Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y12-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI)

Publication | Closed Access

DOI

Citations

References

2010

Year

Sergio Leonardi, Sunil V. Rao, Robert A. Harrington, Deepak L. Bhatt, C. Michael Gibson, Matthew T. Roe, Janusz Kochman, Kurt Huber, Uwe Zeymer, Mina Madan,

American Heart Journal

ThrombosisPercutaneous Coronary InterventionCardiovascular DiseaseReversible P2y12-receptor InhibitorVersus ClopidogrelPharmacologyCardiovascular PharmacologyClinical TrialsDouble-blind TrialCardiologyPharmacotherapyPlatelet AntagonistMedicineAnticoagulantAtherosclerosisCoronary Artery DiseaseAcute Myocardial Infarction